China's diabetes devices market is projected to grow from USD 7.19 billion in 2025 to USD 14.51 billion by 2034, with a CAGR of 8.11%. Growth is driven by rising diabetes prevalence (118 million patients), aging population, government healthcare reforms, and technological advancements in glucose monitoring and insulin delivery systems. Key challenges include cost sensitivity and uneven reimbursement coverage across regions.

The US eosinophilic esophagitis market is projected to grow at 13.2% CAGR through 2036, driven by increased disease awareness, standardized diagnostics, and high relapse rates. The market was valued at $647 million in 2025, with emerging therapies from major pharmaceutical companies expected to transform the treatment landscape, including TSLP inhibitors, glucocorticoid receptor agonists, and immunomodulators.

La Commission européenne a approuvé Dupixent (dupilumab) pour traiter l'urticaire chronique spontanée modérée à sévère chez les enfants âgés de 2 à 11 ans. Cette approbation élargit l'utilisation du médicament, qui inhibe la signalisation de l'IL-4 et de l'IL-13, et en fait le premier traitement ciblé pour cette indication pédiatrique en Europe. Les données cliniques montrent une réduction significative de l'activité de l'urticaire par rapport au placebo.

The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2-11 years, expanding its previous approval for adults and adolescents. The approval is based on the LIBERTY-CUPID clinical study program, demonstrating significant reduction in urticaria activity compared to placebo. This marks Dupixent's fourth approval for young children with type 2 inflammation-driven diseases.

The atopic dermatitis market across seven major markets (US, France, Germany, Italy, Spain, UK, Japan) is projected to grow from $8.5 billion in 2023 to $21.5 billion by 2033, with a CAGR of 9.8%. Growth will be driven by seven late-stage pipeline drugs, expanded treatment options across all age groups and severities, and novel mechanisms of action including JAK inhibitors and IL-inhibiting biologics.

The global atopic dermatitis market is expected to grow from $10.8 billion in 2023 to $26.2 billion by 2033, driven by seven late-stage pipeline agents, expanded treatment options across demographics, and high treatment rates in key markets. The market will grow at a CAGR of 9.3% over the forecast period.

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million (down from $18.5 million YoY) and net loss of $87.2 million. The company is advancing its registrational program for bexobrutideg with Phase 2 DAYBreak CLL-201 enrollment ongoing for accelerated approval in relapsed/refractory CLL, and plans to initiate Phase 3 DAYBreak CLL-306 by mid-2026. Nurix maintains a strong cash position of $540.7 million and is expanding bexobrutideg into immunology/inflammation indications with a new tablet formulation targeting 2026 IND submission.

Biogen has entered into an agreement with Alloy Therapeutics to accelerate the development of antisense therapies for multiple undisclosed indications. Alloy's AntiClastic ASO platform aims to improve the effectiveness of antisense therapeutics by targeting disease pathways at the RNA level. This partnership follows Alloy's January 2025 collaboration with Sanofi and Biogen's recent acquisition of Apellis Pharmaceuticals for $5.6 billion.

Sanofi reported positive Phase 2 data for lunsekimig, its bispecific antibody targeting TSLP and IL-13. The drug met primary endpoints in asthma and nasal polyp studies with significant improvements in exacerbations and polyp size. However, an atopic dermatitis trial missed its primary endpoint, though secondary measures showed some clinical activity. The drug demonstrated a favorable safety profile across all studies.

Sanofi announced that lunsekimig, a bispecific antibody targeting TSLP and IL-13, met primary and key secondary endpoints in phase 2 studies for moderate-to-severe asthma (AIRCULES) and chronic rhinosinusitis with nasal polyps (DUET). The drug demonstrated statistically significant reductions in exacerbations and improvements in lung function. However, the exploratory VELVET study in atopic dermatitis did not meet its primary endpoint, though secondary endpoints showed improvements. Lunsekimig was well tolerated across all studies.

Sanofi announced that lunsekimig, a novel bispesific Nanobody, met primary and key secondary endpoints in Phase 2b AIRCULES study for moderate-to-severe asthma and Phase 2a DUET study for chronic rhinosinusitis with nasal polyps. The drug demonstrated statistically significant reductions in exacerbations and improved lung function. However, the exploratory Phase 2b VELVET study in atopic dermatitis failed to meet its primary endpoint. Lunsekimig was generally well-tolerated across all studies.